Recently, Guangzhou Reforgene Medicine Co., Ltd., an enterprise from Nakin park, announced the completion of hundreds of millions of RMB of Pre-B financing. This round of funding will be used to accelerate clinical trials of thalassemia drugs, and will continue to promote the development of subsequent gene editing drugs and underlying technological innovation.

Founded in 2019, Reforgene is an outstanding representative enterprise of young entrepreneurs in Guangzhou, Hong Kong and Macao. It is committed to the development of emerging gene editing drugs. By virtue of its deep-rooted technical innovation ability and excellent talent team, its lead product, β-thalassemia gene editing drug RM-001, has obtained the tacit approval implied license of the State Food and Drug Administration in November 2022. Phase I clinical trials are currently underway.This product is a cure for transfusion-dependent β-thalassemia disease. All the thalassemia patients treated in early clinical studies have been cured, and all the patients are in good health and have returned to normal life.As the first global clinical study of a new target of thalassemia gene drug, its data is of the world's leading level and was published in the 27th annual conference of The European Hematology Association(EHA) in 2022 and the 64th annual conference of   American Society of Hematology(ASH) in 2022.This is the first Chinese enterprise to announce the clinical research results of thalassemia in two major international (European/American) hematology annual meetings. It has also achieved the first successful treatment of adult thalassemia patients in China.